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Background
Cambodia has scaling up a large national ART program
using 1st line therapy (d4T or AZT+3TC+NVP or EFV).
According to NCHADS, as December 31st 2008, 3,067
children were on HAART in Cambodia, 746 of them were
followed-up in Child Health Improvement Clinic (CHIC)
at the National Pediatric Hospital, (NPH), with French
Red Cross technical support. Fifthy-three out of 746
already switched on LPVr-based 2nd line regimen.
Objective
The aim of this study was to evaluate virological and
immunological outcomes of these children on second
line.
Methods
Retrospective analysis based on data and medical records
from a cohort followed at CHIC to 31st December 2008
was conducted. Patients meeting the Cambodian
National Guidelines for the Use of Pediatric ART for treat-
ment failure were evaluated. First line treatment failure
was confirmed based on clinical and immunological fail-
ure and/or virological failure. Plasma viral load has been
assessed by HIV RNA real time PCR using 2nd generation
ANRS Kit. Genotypic resistance analysis was done at Insti-
tute Pasteur according to ANRS algorithm (v.sep.07).
Results
53/746 patient (7.1%) switched to 2nd line were enrolled
in this study (33.9% were females). Median age was 10.9
years (2.1–17.9). Median duration on the 1st line was 2.2
years (0.6–6.3). Median of CD4 percentage at switch was
8.0% and VL was 5.1 log10 (4.0–6.3) with +/- clinical fail-
ure. At switch, 38/53 patients were tested for HIV drug
resistance. HIV Drug resistance analysis revealed that
97.3% (37/38) children were resistant to NVP/EFV,
78.9% to AZT/d4T/3TC/FTC, 47.3% to ABC/ddI, and
10.5% to TDF. Thirty-six of 53 patients (67.9%) received
standard 2nd line regimen (ABC/ddI/LPV/r), 9 (16.9%)
received 3TC/TDF/LPV/r, 4 (7.5%) were on 3TC/AZT/
LPV/r, and 2 (3.7%) on 3TC/ddI/LPV/r. At evaluation,
median duration on 2nd line was 1.0 years (0.1–3.3).
Median CD4% gain on 2nd line regimen were 13.0% (1–
31%) at M6 (n = 34); 17.0% (1–33) at M12 (n = 27);
19.5% (12–29) at M18 (n = 12); 20.0% (16–32) at M24
(n = 7); and 18.0% (17–28) at M30 (n = 3). Children who
achieved undetectable VL (VL<2.4 log10) at M2 were
71.0% (n = 38); 85.2% at M6 (n = 34); 88% at M12 (n =
25), 77.7% at M18 (n = 9); 85.5% at M24 (n = 7) and
100% at M30 (n = 3).
Conclusion
These preliminary data on Cambodian HIV infected chil-
dren on LPV/r-based second line HAART regimen indi-
cated good virological/immunological responses
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